Gland Pharma Ltd (GLAND) — Board Meeting | 1 October 2026

1 October 2026 · BSE 🟡 Notable Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Board approved $21M U.S. expansion investment and director changes

🔄 What Changed

Added U.S. subsidiary Novelstar; replaced Wenjie Zhang with Xingli Wang; realigned committees

🔮 What's Next

Novelstar acquisition completion targeted by October 31, 2026

💡 Investor Takeaway

U.S. expansion may dilute shares but aims for long-term growth in a key market.

Gland Pharma announced a $21 million investment in Gland Pharma USA Inc. to acquire a 60% stake in Novelstar Pharma Inc., a new U.S. subsidiary, aiming to expand its U.S. footprint. The board accepted the resignation of Director Wenjie Zhang and appointed Xingli Wang as a new non-executive director effective October 1, 2026. Committee realignments followed these changes. This strategic move targets U.S. market entry with Novelstar becoming a step-down subsidiary, though financial impact remains undisclosed.

📄 View Original Announcement (PDF)

📊 Stock Analysis — GLAND ✨ Ask AI About This

About Gland Pharma Ltd (GLAND)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹47,904.29 CrP/E: 42.4ROE: 10.9%ROCE: 15.2%Div Yield: 0.69%

View full GLAND stock details →

📡 Get AI alerts when GLAND files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLAND — Free

💡 Ask AI about this filing

"How will the $21M investment affect Gland Pharma's EPS and share price?""What is the valuation of Novelstar Pharma Inc. post-acquisition?""How does Xingli Wang's pharma experience align with Gland Pharma's U.S. strategy?"

Ask AI Free →

📊 More GLAND filings

Announcement — 30 September 2026Gland Pharma Ltd announced that its trading window closes on October 1, 2026, ahead of the unaudited...
🟡 Board Meeting — 13 September 2026Gland Pharma announced on September 13, 2026 that its Board approved the grant of 5,90,249 stock opt...
🔴 Corporate Action — 13 September 2026Gland Pharma announced on September 13, 2026, that its board approved acquiring 100% of Gland Pharma...
🔴 Corporate Action — 13 September 2026Gland Pharma announced the allotment of 42,393 equity shares under ESOP 2025 and 1,800 shares under ...
🟡 Board Meeting — 13 September 2026Gland Pharma's board addressed fines from NSE and BSE totaling **₹70,000 each** for a 34-day technic...

See all GLAND filings →

🔥 Also filed on 1 October 2026

PVPPVP Ventures LtdAnnouncement 501261Lords Mark Industries LimitedInsider Trading AVALONAvalon Technologies LtdInsider Trading GCSLGretex Corporate Services LtdOffer Document GOPALGopal Snacks LtdAnnouncement HINDZINCHindustan Zinc LtdInsider Trading

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLAND files new disclosures

Track GLAND filings, board meetings, and corporate actions. Free email alerts at 5 PM.